Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Janux Therapeutics Inc (JANX) and BioLife Solutions (BLFS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NeurAxis, Inc. (NRXS – Research Report), Janux Therapeutics Inc (JANX – Research Report) and BioLife Solutions (BLFS – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NeurAxis, Inc. (NRXS)
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on NeurAxis, Inc.. The company’s shares closed last Tuesday at $4.85.
According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of
NeurAxis, Inc. has an analyst consensus of Moderate Buy.
See the top stocks recommended by analysts >>
Janux Therapeutics Inc (JANX)
William Blair analyst Matt Phipps maintained a Buy rating on Janux Therapeutics Inc today. The company’s shares closed last Tuesday at $12.98.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Janux Therapeutics Inc with a $52.58 average price target.
BioLife Solutions (BLFS)
Northland Securities analyst Carl Byrnes maintained a Buy rating on BioLife Solutions today and set a price target of $34.00. The company’s shares closed last Tuesday at $21.82.
According to TipRanks.com, Byrnes has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioLife Solutions with a $33.25 average price target, representing a 50.5% upside. In a report issued on February 12, Lake Street also maintained a Buy rating on the stock with a $33.00 price target.
